CN101310750A - 一种治疗软组织损伤的外用药物及其制备方法 - Google Patents
一种治疗软组织损伤的外用药物及其制备方法 Download PDFInfo
- Publication number
- CN101310750A CN101310750A CNA2007100413201A CN200710041320A CN101310750A CN 101310750 A CN101310750 A CN 101310750A CN A2007100413201 A CNA2007100413201 A CN A2007100413201A CN 200710041320 A CN200710041320 A CN 200710041320A CN 101310750 A CN101310750 A CN 101310750A
- Authority
- CN
- China
- Prior art keywords
- radix
- soft tissue
- parts
- tissue injury
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 88
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 239000004863 Frankincense Substances 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000009472 formulation Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000002674 ointment Substances 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 241000717739 Boswellia sacra Species 0.000 claims description 14
- 241001057584 Myrrha Species 0.000 claims description 14
- 239000009286 sanguis draxonis Substances 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 11
- 208000010392 Bone Fractures Diseases 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001771 impaired effect Effects 0.000 claims description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 229940057995 liquid paraffin Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 239000003871 white petrolatum Substances 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 3
- 240000001972 Gardenia jasminoides Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 30
- 230000036407 pain Effects 0.000 abstract description 28
- 230000008961 swelling Effects 0.000 abstract description 24
- 239000008280 blood Substances 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 19
- 206010017076 Fracture Diseases 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 230000003213 activating effect Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 2
- 241000130781 Arnebia Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 240000005717 Dioscorea alata Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241001369613 Stephania tetrandra Species 0.000 abstract 1
- 206010042674 Swelling Diseases 0.000 abstract 1
- 230000035587 bioadhesion Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 8
- 206010014080 Ecchymosis Diseases 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 230000000399 orthopedic effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- KQPKPCNLIDLUMF-UHFFFAOYSA-N secobarbital Chemical compound CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-UHFFFAOYSA-N 0.000 description 2
- 229960002060 secobarbital Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010064470 Muscle swelling Diseases 0.000 description 1
- 206010053156 Musculoskeletal discomfort Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100413201A CN101310750B (zh) | 2007-05-25 | 2007-05-25 | 一种治疗软组织损伤的外用药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100413201A CN101310750B (zh) | 2007-05-25 | 2007-05-25 | 一种治疗软组织损伤的外用药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101310750A true CN101310750A (zh) | 2008-11-26 |
CN101310750B CN101310750B (zh) | 2012-01-04 |
Family
ID=40099707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100413201A Expired - Fee Related CN101310750B (zh) | 2007-05-25 | 2007-05-25 | 一种治疗软组织损伤的外用药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101310750B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972384A (zh) * | 2010-11-05 | 2011-02-16 | 胡怀强 | 一种治疗急性软组织损伤的膏药及其制备方法 |
CN106421540A (zh) * | 2016-12-28 | 2017-02-22 | 四川默森药业有限公司 | 一种用于软组织损伤的贴剂及其制备方法 |
CN107050242A (zh) * | 2017-04-24 | 2017-08-18 | 河南科技学院 | 治疗急性软组织损伤的中药组合物、制备方法及其应用 |
CN108175820A (zh) * | 2018-01-17 | 2018-06-19 | 上海方心健康科技发展股份有限公司 | 一种中药乳膏剂及其制备方法 |
-
2007
- 2007-05-25 CN CN2007100413201A patent/CN101310750B/zh not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972384A (zh) * | 2010-11-05 | 2011-02-16 | 胡怀强 | 一种治疗急性软组织损伤的膏药及其制备方法 |
CN101972384B (zh) * | 2010-11-05 | 2011-10-05 | 胡怀强 | 一种治疗急性软组织损伤的膏药及其制备方法 |
CN106421540A (zh) * | 2016-12-28 | 2017-02-22 | 四川默森药业有限公司 | 一种用于软组织损伤的贴剂及其制备方法 |
CN107050242A (zh) * | 2017-04-24 | 2017-08-18 | 河南科技学院 | 治疗急性软组织损伤的中药组合物、制备方法及其应用 |
CN107050242B (zh) * | 2017-04-24 | 2020-11-13 | 河南科技学院 | 治疗急性软组织损伤的中药组合物、制备方法及其应用 |
CN108175820A (zh) * | 2018-01-17 | 2018-06-19 | 上海方心健康科技发展股份有限公司 | 一种中药乳膏剂及其制备方法 |
CN108175820B (zh) * | 2018-01-17 | 2020-08-25 | 上海方心健康科技发展股份有限公司 | 一种中药乳膏剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101310750B (zh) | 2012-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102228485A (zh) | 用于烧伤康复的组合物及其制备方法 | |
CN100446796C (zh) | 治疗骨折的外用药物 | |
CN101181568B (zh) | 一种治骨质增生及关节疼痛的中药制剂 | |
CN104258278B (zh) | 骨伤灵喷雾剂 | |
CN101310750B (zh) | 一种治疗软组织损伤的外用药物及其制备方法 | |
CN103463580B (zh) | 治疗经筋、骨、关节疼痛的中药膏及其制备方法 | |
CN102895601A (zh) | 一种治疗颈肩部疼痛的药物 | |
CN105213906A (zh) | 一种用于治疗痛风的中药组合物及其制备方法 | |
CN112057585A (zh) | 含有多种精油治疗颈肩腰腿痛的贴剂配方及其制备方法 | |
CN102188550B (zh) | 一种治疗筋骨伤病的外用制剂 | |
CN103191330A (zh) | 用于治疗偏瘫患者肢体肿胀的中药 | |
CN103127287A (zh) | 一种治疗湿疹的中药组合物 | |
CN103142795B (zh) | 一种治疗股骨头缺血性坏死的中药药剂 | |
CN101194985B (zh) | 一种内服用于治疗膝关节骨质增生的中药组合物 | |
CN102406893A (zh) | 一种治疗银屑病的中成药 | |
CN102218094B (zh) | 一种治疗跌打损伤的中药制剂及其制备方法 | |
CN104873615A (zh) | 一种含肉桂油治疗跌打损伤的外用药 | |
CN103908508B (zh) | 一种脚气康复药剂 | |
CN103070994B (zh) | 一种治疗颈椎腰椎病的膏药 | |
CN100478007C (zh) | 跌打风湿增生膏及其制备方法 | |
CN116870076B (zh) | 一种抗炎镇痛中药组合物及其制备方法与应用 | |
CN108785421A (zh) | 一种用于治疗骨折的中药配方及其制法 | |
CN101244181A (zh) | 具有袪风胜湿、活血化瘀、通络止痛的骨痹症膏药及其制备方法 | |
CN105412395A (zh) | 一种治疗骨质增生的中药组合物及其制备方法 | |
CN104666653A (zh) | 一种治疗膝盖骨关节炎的中药膏剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT CO. Free format text: FORMER OWNER: SHANGHAI FANGXIN TECHNOLOGY INSTITUTE Effective date: 20130306 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200032 XUHUI, SHANGHAI TO: 200030 XUHUI, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130306 Address after: 200030 13C room, No. 69, Xuhui District Medical College, Shanghai, China Patentee after: Shanghai Fangxin Health Technology Development Co., Ltd. Address before: 200032 Shanghai Xietu Road No. 1755 room 888 Patentee before: Shanghai Fangxin Technology Institute |
|
CP01 | Change in the name or title of a patent holder |
Address after: 200030 13C room, No. 69, Xuhui District Medical College, Shanghai, China Patentee after: SHANGHAI FANGXIN HEALTH TECHNOLOGY DEVELOPMENT CO., LTD. Address before: 200030 13C room, No. 69, Xuhui District Medical College, Shanghai, China Patentee before: Shanghai Fangxin Health Technology Development Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120104 Termination date: 20210525 |
|
CF01 | Termination of patent right due to non-payment of annual fee |